Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 222   

Articles published

SNY 48.95 +0.84 (1.75%)
price chart
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.
Sanofi SA (ADR), Evotec Enter Into €250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth €250 million.
Company Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi SA (ADR ...
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR)(NYSE:SNY) have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.
Sanofi SA And Regeneron Pharmaceuticals Extend Partnership In Cancer Treatments  Bidness ETC
Sanofi SA (ADR) And Regeneron's $2.2B Pursuit Of Immuno-Oncology Drugs ...  International Business Times
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
According to a report compiled by data analytics firm GlobalData, the 10 leading diabetes drug-makers generated around $62 billion in 2014 global sales, up 5.1% year-over-year (YoY).
Sanofi SA Wins Breakthrough Therapy Designation For Novel Rare Disease Drug
Sanofi SA's (ADR) (NYSE:SNY) subsidiary Genzyme announced Thursday that its novel rare disease drug Olipudase Alfa has won breakthrough therapy designation from the US Food and Drug Administration (FDA).
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs
Sanofi SA (ADR) (NYSE:SNY) the $130 billion French drug manufacturer, is trying desperately to maintain its position as a leader in diabetes drugs.
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin  Bidness ETC
Sanofi SA (ADR) Reports Positive Cardiovascular Safety Results For Diabetes ...
Sanofi SA (ADR) (NYSE:SNY) announced Thursday positive results for its diabetes drug Lyxumia from a Phase III study evaluating the cardiovascular risks of the said drug.
Why Sanofi SA (ADR) Doesn't Consider Acquisitions Essential For Future Growth
The French pharmaceutical giant, Sanofi SA (ADR) (NYSE:SNY), after considering various acquisition options, has reached the conclusion that takeovers and various deal-making opportunities would not be the most essential growth driver for the company in ...
VBI Vaccines Inc. (VBIV) Shares Soar After Partnership With Sanofi SA (ADR)
VBI Vaccines Inc. (NASDAQ:VBIV) jumped more than 20% in after-hours trade on Monday, following an announcement that the vaccines division of Sanofi SA (ADR) (NYSE:SNY), Sanofi Pasteur, will apply VBI's LPV™ (Lipid Particle Vaccine) formulation ...
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY ...
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY). The veteran portfolio manager has an impressive track-record of managing to ...